"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Descriptor ID |
D018719
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
|
Concept/Terms |
Receptor, ErbB-2- Receptor, ErbB-2
- ErbB-2 Receptor
- Antigens, CD340
- CD340 Antigens
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- p185(c-neu)
- c-erbB-2 Protein
- c erbB 2 Protein
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Receptors, erbB-2
- erbB-2 Receptors
- Neu Receptor
- Receptor, Neu
- Metastatic Lymph Node Gene 19 Protein
- Proto-oncogene Protein Neu
- Neu, Proto-oncogene Protein
- Proto-oncogene c-ErbB-2
- c-ErbB-2, Proto-oncogene
- Tyrosine Kinase-type Cell Surface Receptor HER2
- Tyrosine Kinase type Cell Surface Receptor HER2
- p185erbB2 Protein
- CD340 Antigen
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-2 [D12.776.543.750.630.009.400]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Receptor, ErbB-2 [D23.050.301.500.600.700]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Receptor, ErbB-2 [D23.050.705.552.600.550]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-2 [D23.101.140.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".
This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
1998 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2004 | 2 | 1 | 3 |
2005 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2009 | 1 | 1 | 2 |
2010 | 3 | 0 | 3 |
2011 | 0 | 1 | 1 |
2012 | 4 | 2 | 6 |
2013 | 2 | 0 | 2 |
2014 | 0 | 3 | 3 |
2015 | 1 | 0 | 1 |
2016 | 4 | 1 | 5 |
2017 | 4 | 3 | 7 |
2018 | 0 | 4 | 4 |
2019 | 1 | 0 | 1 |
2020 | 0 | 3 | 3 |
2021 | 1 | 4 | 5 |
2022 | 0 | 4 | 4 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.
-
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 05 27; 401(10390):1773-1785.
-
New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):54-61.
-
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. Eur J Cancer. 2022 09; 172:13-21.
-
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open. 2022 06; 7(3):100495.
-
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer. 2022 06; 126(12):1715-1724.
-
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2022 02; 162:45-55.
-
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021 12; 6(6):100299.
-
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer. 2021 09; 155:1-12.
-
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. Eur J Cancer. 2021 09; 154:128-137.
-
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046. J Cancer Res Clin Oncol. 2021 Nov; 147(11):3391-3400.